A CE-certified ear-clip vagus nerve stimulator from London neurotech startup Parasym, backed by 60+ clinical studies with Harvard, UCLA, and NHS research partners.
Nurosym is a non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that clips onto the tragus of the ear and delivers gentle electrical pulses through Parasym's proprietary AVNT waveform, aimed at stress regulation, sleep, fatigue, and autonomic balance. It targets the auricular branch of the vagus nerve, a pathway distinct from neck-worn competitors like Pulsetto or gammaCore, with 45 intensity levels and 30-60 minute sessions requiring no gel. The device is CE-certified under EU MDR as a medical neuromodulation wearable, priced around $729 with replacement electrodes, sold direct via nurosym.com from the Netherlands with a 30-day money-back guarantee. Its key differentiation is evidence: 60+ completed studies including gold-standard placebo-controlled trials, collaborations with Harvard, UCLA, Bart's Health NHS Trust, and the University of Chicago, and ongoing long-COVID and POTS research. It is the most clinically validated consumer tVNS device on the market, though it remains CE-marked without FDA clearance.
Parasym was founded in London in 2018 by a team including co-founder Nathan Dundovic to commercialize a decade of auricular vagal neuromodulation research; it spent its early years embedded in academic and clinical studies rather than consumer marketing. The company later launched the Nurosym brand to consumers, riding the post-pandemic wave of interest in nervous system regulation, long COVID, and burnout recovery, particularly among biohackers and chronic-fatigue communities. Adoption grew through practitioner recommendations, over 1,000 certified healthcare professionals now endorse or use it, and research partnerships, rather than mass advertising. The device has accumulated 5 million+ user sessions, a Trustpilot base of 1,100+ reviews, and a next-generation NuroPod model launched in 2025. Nurosym remains a lean, research-first team whose credibility moat is its clinical database, the largest in consumer neuromodulation.
Figures are compiled from public sources and may include estimates. Always verify before making business decisions.
Health & Beauty
Kickstarter (Apollo 2.0)$1,179,308 from 2,804 backers
Apollo Neuro, founded in 2014 by psychiatrist Dr. Dave Rabin and Kathryn Fantauzzi, sells a $349 vibration wearable that helps the body recover from stress. Its Apollo 2.0 Kickstarter raised $1,179,308 from 2,804 backers, after a $15M Series A at a valuation above $100M.
Health & Beauty
Indiegogo launch (2022)~EUR 250,000 raised; funded on day one
Pulsetto, founded in Lithuania in 2021, makes a transcutaneous vagus nerve stimulator worn on the neck for four-minute stress and sleep sessions. An Indiegogo launch funded on day one and raised roughly EUR 250,000, and the brand reports 3x year-over-year growth for three straight years and 100,000+ users.
Health & Beauty
Revenue run rate (mid-2026)$100M+ (from under $10M in 2022)
Boka, founded in 2015 by James Hagen, sells fluoride-free nano-hydroxyapatite toothpaste with skincare-style flavors and ingredients. It grew from under $10M revenue in 2022 to a $100M+ annual run rate by mid-2026 and became the top-selling toothpaste on Amazon in 2024.